Retatrutide FDA Approval History

Current FDA Status: Not Yet Approved

Retatrutide has not received FDA approval for any indication as of May 2026. The molecule remains classified as an investigational new drug (IND) under Eli Lilly's clinical development program 1. Unlike tirzepatide, which received FDA approval as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for obesity in November 2023 2, retatrutide is still progressing through late-stage clinical evaluation.

The FDA has not issued a Refuse to File letter or Complete Response Letter for retatrutide because Eli Lilly has not yet submitted a New Drug Application (NDA). The company's regulatory strategy appears to hinge on completing phase 3 readouts across multiple indications before filing 3. This approach mirrors what Lilly did with tirzepatide, pursuing diabetes and obesity indications in sequence rather than bundling them into a single submission 4.

What Makes Retatrutide Different: Triple Receptor Agonism

Retatrutide is the first triple-hormone receptor agonist to reach phase 3 development. It activates three receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon 1. Dual agonists like tirzepatide target GIP and GLP-1 only 5. The addition of glucagon receptor activation is hypothesized to increase energy expenditure and promote hepatic fat oxidation, producing weight loss through mechanisms that dual agonists do not fully engage 6.

This triple mechanism is why regulatory and clinical interest in retatrutide has been high. The glucagon component could differentiate retatrutide's metabolic profile from existing GLP-1 and dual-agonist therapies, though this advantage must be confirmed in head-to-head phase 3 comparisons 7.

Phase 2 Trial: The Data That Shaped the Regulatory Path

The phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine (June 2023) enrolled 338 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity 1. Participants received one of several retatrutide doses (1, 4, 8, or 12 mg) or placebo via weekly subcutaneous injection for 48 weeks.

Results were striking. The 12 mg dose group lost a mean of 24.2% of body weight at 48 weeks, compared to 2.1% in the placebo group 1. That degree of weight reduction exceeded the 22.5% seen with tirzepatide 15 mg in the SURMOUNT-1 trial at 72 weeks 8, though cross-trial comparisons carry significant limitations because of differences in populations, trial duration, and dose-escalation schedules.

Among participants receiving retatrutide 12 mg, 100% achieved at least 5% body-weight loss and 83% achieved at least 15% 1. These response rates caught the attention of the FDA review division responsible for metabolic and endocrine products.

Safety Profile From Phase 2

Gastrointestinal adverse events were the most common side effects across all retatrutide dose groups, consistent with GLP-1 receptor agonist class effects. Nausea occurred in 16% to 46% of retatrutide-treated participants (dose-dependent), compared to 10% in the placebo group 1. Diarrhea and vomiting were also reported at higher rates with active treatment.

The events were predominantly mild to moderate in severity and declined after the dose-escalation period. Discontinuation rates due to adverse events were relatively low: approximately 6% across retatrutide groups 1. No pancreatitis cases were confirmed. Heart rate increased by a mean of 2 to 4 beats per minute in the higher-dose groups, a finding observed with other incretin-based therapies 9.

The FDA will likely require detailed cardiovascular outcome data before granting full approval, as the agency mandated cardiovascular outcome trials (CVOTs) for GLP-1 receptor agonists following the rosiglitazone experience 10. Whether Lilly can obtain initial approval before a CVOT completes, as Novo Nordisk did with semaglutide 2.4 mg (Wegovy), remains a strategic regulatory question 11.

Phase 2 in Type 2 Diabetes

A separate phase 2 trial evaluated retatrutide in 281 adults with type 2 diabetes inadequately controlled on metformin. Published results showed HbA1c reductions of up to 2.02 percentage points at 36 weeks with retatrutide 12 mg, compared to 0.01 points with placebo 12. Participants in the highest-dose group also lost 16.9% of body weight. These glucose-lowering effects are competitive with tirzepatide's performance in the SURPASS trials 13.

The glycemic data support a potential type 2 diabetes indication, though the FDA pathway for an obesity indication is expected to be the primary regulatory target given market dynamics and Lilly's existing tirzepatide franchise for diabetes.

The TRIUMPH Phase 3 Program

Eli Lilly launched the TRIUMPH phase 3 program to evaluate retatrutide across multiple indications. Registered trials on ClinicalTrials.gov include studies in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD) 3.

The obesity key trials are expected to enroll several thousand participants, a scale comparable to the SURMOUNT program for tirzepatide (N ≥ 4,500 across four trials) 14. The FDA's 2023 guidance for obesity drug development recommends trials of at least 12 months' duration with co-primary endpoints of percent body-weight change and the proportion of participants achieving at least 5% weight loss 15.

MASLD represents a potentially significant regulatory path because no FDA-approved pharmacotherapy specifically targets liver fibrosis in MASLD patients, aside from resmetirom (Rezdiffra), which received accelerated approval in March 2024 for MASH with moderate-to-advanced fibrosis 16. The glucagon receptor agonism in retatrutide is hypothesized to drive hepatic fat clearance more aggressively than GLP-1-only or dual-agonist compounds 7.

Projected Regulatory Timeline

Based on typical phase 3 trial durations and FDA review cycles, the earliest plausible NDA submission for retatrutide would be late 2026 or 2027, depending on enrollment speed and data maturity. The FDA's standard review period for a new molecular entity is 10 months from submission under the Prescription Drug User Fee Act (PDUFA), though a priority review designation could shorten this to 6 months 17.

Retatrutide has not received Breakthrough Therapy designation from the FDA as of the latest public disclosures. However, its weight-loss efficacy in phase 2 could support such a designation request, as the FDA granted Breakthrough status to tirzepatide for obesity based on phase 3 data showing substantial improvement over existing therapies.

If the NDA is filed in 2027, an approval decision could come by mid-to-late 2028. Investors and clinicians tracking Eli Lilly's quarterly earnings calls and clinical-trial registry updates will have the most current information on any shifts in this timeline.

What the Retatrutide Label Might Include

No prescribing label exists yet because the drug is not approved. However, based on phase 2 data and FDA precedent with tirzepatide and semaglutide, the label would likely include a boxed warning about the risk of thyroid C-cell tumors, given GLP-1 receptor agonist class labeling requirements 18. This boxed warning is present on all approved GLP-1 receptor agonists in the United States, based on rodent studies showing thyroid C-cell tumor formation.

Anticipated label sections would include dosing with a gradual dose-escalation schedule (likely 4 to 12 weeks, as used in the phase 2 trial), contraindications for patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome, and warnings regarding gastrointestinal adverse events, pancreatitis risk, and gallbladder-related events 18.

The glucagon receptor component may prompt the FDA to request additional labeling language about hepatic effects, glycogen mobilization, and theoretical risks of hyperglycemia in non-diabetic patients, though no clinically meaningful hyperglycemia was reported in phase 2 participants without diabetes 1.

How Retatrutide Fits in the Incretin Drug Pipeline

The FDA has approved several incretin-based therapies over the past decade. Semaglutide (Wegovy) received approval for chronic weight management in June 2021 11. Tirzepatide (Zepbound) followed for obesity in November 2023 2. Oral semaglutide (Rybelsus) is approved for type 2 diabetes at doses up to 14 mg 19, and a higher 50 mg oral dose is under review for both diabetes and obesity.

Retatrutide occupies a distinct pharmacological position as the only triple agonist in late-stage development. Survodutide (Boehringer Ingelheim), a dual GLP-1/glucagon agonist, is also in phase 3 and represents indirect competition for the glucagon-receptor mechanism 20. The FDA's willingness to approve drugs with overlapping mechanisms but distinct efficacy profiles suggests retatrutide could receive approval even in a crowded incretin market, provided phase 3 data confirm the phase 2 signals.

Dr. Ania Jastreboff, lead investigator on the phase 2 obesity trial, stated: "The magnitude of weight reduction observed with retatrutide, including the near-complete response rates at the highest dose, suggests that triple-hormone receptor agonism may offer a differentiated therapeutic profile" 1.